Efficacy of Tocilizumab in Primary Sjögren's Syndrome. — ETAP  

Primary Sjögren's Syndrome (pSS) Clinical Trial

Official title: A Randomized, Double-blind, Parallel, Placebo-controlled Trial to Evaluate the Efficacy of Tocilizumab for the Treatment of Primary Sjögren's Syndrome.

Status Completed

Clinical Trial Summary

Primary Sjögren's syndrome (pSS) is a systemic autoimmune disease characterized by lymphocytic infiltration leading to destruction of acinar and ductal cells and loss of glandular parenchyma. The main symptoms of pSS are dry eyes and dry mouth, diffuse pain, and fatigue. One third of patients develop systemic features, the most severe being lymphomas.

Serum IL-6 is increased in serum, saliva, and tears of patients with pSS. IL-6 plays a pivotal role in B-cell activation, a hallmark of the pathogenesis of pSS, and in T-cell differentiation. Tocilizumab, a recombinant humanised monoclonal antibody acts as an IL-6R antagonist. The aim of this randomised double blind placebo controlled trial iss to evaluate the efficacy of tocilizumab for the treatment of pSS.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Primary Sjögren's Syndrome (pSS)
• Sjogren's Syndrome
• Syndrome

• NCT number: NCT01782235
• Study type: Interventional
• Source: University Hospital, Strasbourg, France
• Status: Completed
• Phase: Phase 2/Phase 3
• Start date: July 24, 2013
• Completion date: July 16, 2018